Sema Overview

Sema, also known as Semaglutide, is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that is structurally modified for extended activity. It is studied in laboratory and preclinical models for its ability to activate GLP-1 receptors, regulate insulin signaling, and modulate cellular pathways associated with glucose metabolism and endocrine regulation.

Marso S.P. et al. (2016).

History

Research into GLP-1 biology began in the 1980s with the identification of its role in glucose regulation and endocrine signaling. Early synthetic GLP-1 receptor agonists demonstrated promise in extending receptor activation, but limited half-life restricted their utility. Semaglutide was later developed with structural modifications at specific amino acid positions to improve receptor binding and extend duration of action, making it a useful tool for studying incretin biology and metabolic pathways in research models.

Knudsen L.B. et al. (2000).

Semaglutide Structure

CAS #: 910463-68-2

Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉

Molecular Weight: 4113.6 g/mol

PubChem ID: 56843331

Research Findings

Sema, also known as Semaglutide, has been studied in metabolic, endocrine, and cardiovascular models, with research highlighting its activity in glucose regulation, insulin secretion, and weight management pathways. Studies have also reported effects on lipid metabolism, appetite regulation, and cardiovascular outcomes in preclinical and clinical settings.

Key Areas of Research:

• Metabolic: glucose, insulin, energy balances

• Endocrine: GLP-1 signaling, hormone regulation

• Cardiovascular: lipid, cholesterol, outcomes

Together, these findings suggest broad experimental potential for Semaglutide across metabolic, endocrine, and cardiovascular pathways. By engaging GLP-1 signaling and influencing glucose and lipid metabolism, Semaglutide provides a versatile platform for research into metabolic regulation, cardiovascular health, and systemic resilience in laboratory models.

Wilding J.P.H. et al., 2021

References

Marso S.P. et al. (2016). Semaglutide and cardiovascular outcomes in research models of GLP-1 receptor activation. N Engl J Med, 375:1834–1844.

Knudsen L.B. et al. (2000). Design and structure–activity relationship of Semaglutide, a modified GLP-1 analog. J Med Chem, 43(9):1664–1669.

Davies M. et al. (2017). Semaglutide and systemic endocrine effects in type 2 diabetes research studies. Lancet, 389(10072):1407–1418.